BPC 157 costs about $114 to $249 a month, membership included, at telehealth services that publish a price (October 2026), and “research use only” vials sell for less. Neither is a regulated product: BPC 157 is not FDA-approved, and although it left the FDA's Category 2 list in April 2026, no pharmacy is yet cleared to compound it.[1]
Almost every other “how much does it cost” peptide question has a clean answer because the molecule moves through a regulated supply chain. BPC 157 is the exception, and that is the whole story. You cannot quote its price honestly without first explaining where it sits in the regulatory landscape, because that single fact — not the molecule, not the dose, not the brand — is what sorts the cheapest listings from the most expensive ones. So before any number, the status.
Not on 503A list
Off FDA’s Category 2 list since April 2026, but not yet cleared for pharmacy compounding
FDA Category 2 list and 503A nominations
Not approved
BPC 157 is FDA-approved for no human use, anywhere
Unverified
Actual content of “research use only” gray-market vials
Why does regulatory status set the BPC 157 price?
BPC 157 is a synthetic pentadecapeptide marketed for tissue repair, but it has never been approved as a drug. When the FDA reviewed substances nominated for use in pharmacy compounding under section 503A, it sorted BPC 157 into Category 2 — the bucket for substances that raise significant safety concerns — rather than the category that lets a compounding pharmacy legally prepare it for patients.[1] The FDA removed it from Category 2 in April 2026 after its nomination was withdrawn, but removal is not clearance: BPC 157 is still not on the 503A bulks list, and a July 2026 advisory-committee vote to recommend adding it is non-binding. The practical effect of those years in Category 2 was to strip BPC 157 out of the part of the market where a licensed pharmacist makes a clean, tested, patient-specific preparation, and push it toward the only sellers willing to handle it: websites that stamp the vial “research use only — not for human use.”
That is why BPC 157 pricing breaks the usual pattern. For most peptides, the regulated route is the baseline and the gray market is a fringe. For BPC 157 the gray market is the dominant retail channel, and the small number of clinics still dispensing it are the outliers carrying the legal and sourcing risk. So the price you see depends almost entirely on which side of that line you are looking at — and the cheap side is cheap precisely because the safeguards have been removed.
How much does BPC 157 cost by route?
With the status in mind, here is the realistic price picture as of October 2026 — confirm current figures before relying on any of them, because this is an unsettled and lightly policed market.
Gray-market “research” vials are the cheapest on paper. A single vial in the common 5–10 mg size is frequently listed for a low double-digit to low triple-digit dollar figure, and bulk or multi-vial “kits” drive the per-milligram number lower still. That is the entire marketing hook: the headline cost looks like a fraction of any clinical alternative. What the number does not include is any assurance that the powder is BPC 157, that it is the labeled quantity, or that it is free of contaminants — the costs that the regulated routes are largely charging you to absorb.
Telehealth and clinic programs, where you can still find them, sit higher. Among telehealth services that publish a BPC 157 price, the figures we read on their own websites in October 2026 ran from $85 a month for the medication plus a $29 membership (about $114 in total) to $249 a month, and combined “recovery” blends that add TB-500 or other peptides typically cost more. In-person clinics usually price it as a program that also bundles visits and injections, so the total can run higher still. As with any peptide program, much of the fee buys the clinician and the bundle — a dynamic we break down across the category in our peptide therapy cost guide. Note what that price does not buy: because BPC 157 is not yet on the 503A bulks list, a prescription does not make it an FDA-cleared compounded drug.
Swipe to see all columns
| Route | Typical price (October 2026) | What that price actually reflects |
|---|---|---|
| Gray-market “research” vial (5–10 mg) | Lowest per mg; multi-vial kits cheaper still | An unregulated powder of unverified content — the safeguards are what’s missing |
| Telehealth service (published price) | About $114–$249 a month, membership included | The clinician, shipping and the program, plus the seller carrying sourcing and legal risk |
| Blend with TB-500 or other peptides | Usually above the single-peptide price | More compounds and a larger bundle — not a scarcer molecule |
| Compounding pharmacy cleared by FDA | Not available yet | BPC 157 is still not on the 503A bulks list; the July 2026 advisory vote is non-binding |
Why “cheapest per milligram” is the wrong yardstick
The instinct on any cost page is to find the lowest cost per milligram and stop there. For a substance sold mostly as an unregulated powder, that yardstick is actively misleading, and the most relevant data come from the neighboring — and far more studied — gray market for injectable weight-loss drugs. A 2024 market-surveillance study that bought and laboratory-tested semaglutide sold online with no prescription documented exactly the failure modes worth fearing here: unregistered vendors, paid orders that simply never shipped, and tested product whose measured content did not match what the label promised — impurities present, doses off.[2]Nothing about BPC 157’s “research” channel makes it safer than that; if anything, the absence of any approved reference product makes verification harder. A per-milligram price computed on a vial whose true contents are unknown is a confident number wrapped around an unknown quantity.
So the honest reframing is the same one that holds across unregulated peptide sales: a low sticker attached to an unquantified risk is not cheap, it is simply unpriced. For the broader version of that argument — and for what doing this with any care actually looks like — see where to get peptides safely.
The cost you can’t see: there’s almost no human evidence to buy
There is one more line item the sticker hides. With most prescription therapies, your money buys a molecule with demonstrated human benefit. With BPC 157 it does not. The body of evidence is essentially all animal and cell-culture work — there are no published randomized controlled trials in humans for any indication, which means no established dosing, no human efficacy data, and no long-term safety profile. We walk through that literature in full in our BPC 157 evidence review, and we map the human-data gap on the peptide evidence matrix. The point for a cost decision is blunt: whatever you pay, you are paying for promise generated in rodents, not for a proven human outcome.
That changes how to read every price on this page. A research vial isn’t a cheap version of a validated product, and a clinic program isn’t buying you trial-backed efficacy — the trials don’t exist. Before weighing any figure, it’s worth knowing what you’d actually be taking on: see our reads on BPC 157 dosage and safety, BPC 157 side effects, and the honest version of the “before and after” story.
The honest bottom line
BPC 157 doesn’t have a clean price because it doesn’t have a clean regulatory home. Its years in Category 2 of the FDA’s 503A compounding review pushed it out of legitimate compounding-pharmacy supply and into the “research use only” gray market, which is why the cheapest listings — low-double-digit-to-triple-digit research vials — are also the ones with the least accountability, while the telehealth services still offering it charge about $114 to $249 a month (October 2026) for the clinician, the program, and the sourcing risk they carry. The lowest number is the misleading one. And underneath every figure sits the cost you can’t see on the label: there is no controlled human efficacy evidence to buy. If you’re comparing options, compare the legitimate, evidence-graded landscape first — our peptide therapy provider comparison is the place to start.
